EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Temporary Apremilast Induction Bridging During Early Risankizumab Therapy for Psoriasis Flare: A Case Report

Courtney Serini, David Oberlin

SKIN The Journal of Cutaneous Medicine · 10.11.2026 · 10 (6) · 3543-3547

DOI: 10.25251/faz46749 ↗

Kurz gefasst

Fallbericht in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.11.2026. Verfasst von Courtney Serini und 1 weiteren Autor:innen. Die Arbeit nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Risankizumab is a highly effective interleukin-23 (IL-23) inhibitor used in the treatment of moderate-to-severe plaque psoriasis. Although clinical improvement may occur within the first several weeks of therapy, maximal therapeutic responses are often achieved several months after treatment initiation. During this early treatment interval, patients with significant inflammatory burden may continue to experience active disease before the full therapeutic effect of IL-23 inhibition is realized. We report a patient with plaque psoriasis who experienced worsening disease during the early phase of Risankizumab therapy. Despite receiving the initial and second loading dose at Week 4, the patient continued to flare and presented one week later with progression of psoriasis. Rather than initiating systemic corticosteroids, cyclosporine, or transitioning biologic therapy, temporary induction therapy with apremilast was initiated while continuing Risankizumab. The patient reported symptomatic improvement within approximately 1.5 weeks of apremilast initiation and demonstrated substantial clinical improvement at follow-up. The patient ultimately achieved complete disease clearance while continuing Risankizumab therapy. To our knowledge, this is the first published report describing the use of short-term Apremilast induction therapy in combination with Risankizumab to manage inflammatory disease activity during the early treatment phase of IL-23 inhibitor therapy.

Zitieren

APA

Serini, C., & Oberlin, D. (2026). Temporary Apremilast Induction Bridging During Early Risankizumab Therapy for Psoriasis Flare: A Case Report. SKIN The Journal of Cutaneous Medicine, 10(6), 3543-3547. https://doi.org/10.25251/faz46749

Vancouver

Serini C, Oberlin D. Temporary Apremilast Induction Bridging During Early Risankizumab Therapy for Psoriasis Flare: A Case Report. SKIN The Journal of Cutaneous Medicine. 2026;10(6):3543-3547. doi:10.25251/faz46749

BibTeX
@article{Serini2026,
  author = {Serini, Courtney and Oberlin, David},
  title = {Temporary Apremilast Induction Bridging During Early Risankizumab Therapy for Psoriasis Flare: A Case Report},
  journal = {SKIN The Journal of Cutaneous Medicine},
  year = {2026},
  volume = {10},
  number = {6},
  pages = {3543--3547},
  doi = {10.25251/faz46749}
}
Kostenlos starten →